Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Iranian-made Ranibizumab and Imported Ranibizumab in Diabetic Macular Edema
IRCT20170303032845N1Phase 3Completed
- Sponsor
- Ara Cell Zist Daru
- Start
- Dec 2019
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of ranibizumab in diabetic macular edema (DME) and diabetic retinopathy (DR) (2 arms), sponsored by Ara Cell Zist Daru. Primary endpoints: Visual acuity improvement and Reduction in macular thickness. Started Dec 2019; status: completed.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)diabetic retinopathy (DR)
Beyond the preview
Go deeper on IRCT20170303032845N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20170303032845N1.